Cas:384820-17-1 4-[2-(2-bromophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyridine manufacturer & supplier

Chemical Name:4-[2-(2-bromophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyridine

CAS.NO:384820-17-1

Synonyms:4-[2-(2-bromophenyl)-5-(4-fluorophenyl)-1h-imidazol-4-yl]pyridine

Molecular Formula:C₂₀H₁₃BrFN₃

Molecular Weight:394.24000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.457

Index of Refraction:

PSA:41.57000

Exact Mass:393.02800

LogP:5.70730

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-[2-(2-bromophenyl)-5-(4-fluorophenyl)-1h-imidazol-4-yl]pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[2-(2-bromophenyl)-5-(4-fluorophenyl)-1h-imidazol-4-yl]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[2-(2-bromophenyl)-5-(4-fluorophenyl)-1h-imidazol-4-yl]pyridine Use and application,4-[2-(2-bromophenyl)-5-(4-fluorophenyl)-1h-imidazol-4-yl]pyridine technical grade,usp/ep/jp grade.

Related News: In the US, avalglucosidase alfa saw its PDUFA date pushed back by three months, from May 18 to Aug. 18, according to a Sanofi investor presentation in April. calcium 3-(2-(methylamino)-2-oxoethoxy)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate manufacturers After recently opening one cell therapy plant and breaking ground on another in Massachusetts, Takeda is pivoting westward to beef up production in California. 5-methylfuryloctylcarbinol suppliers CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells. (Z)-4-Amino-2-chlorbut-2-ensaeure vendor & factory In the US, avalglucosidase alfa saw its PDUFA date pushed back by three months, from May 18 to Aug. 18, according to a Sanofi investor presentation in April.,Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful.